Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Fenaux, P., Giagounidis, A. A. N., Selleslag, D., Beyne‐Rauzy, O., Mufti, G. J., Mittelman, M., Muus, P., Boekhorst, P. A. W. T., Sanz, G. F., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 497

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

Itzykson, R., Kosmider, O., Cluzeau, T., Mas, V. M., Dreyfus, F., Beyne‐Rauzy, O., Quesnel, B., Vey, N., Gelsi‐Boyer, V., Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 480

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463

A simple p53 functional assay for screening cell lines, blood, and tumors.

Flaman, J., Frébourg, T., Moreau, V., Charbonnier, F., Martin, C., Chappuis, P. O., Sappino, A. P., Limacher, I. M., Bron, L. P., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 455

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne‐Rauzy, O., Turlure, P., Vey, N., Récher, C., Dartigeas, C., Legros, L., et al. (2010) · Blood · doi:10.1182/blood-2010-06-289280 · Cited by 381

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

Shen, L.-L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S. S., Zhu, W., Pierce, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4781 · Cited by 348

Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes

Bejar, R. L., Levine, R. L., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 309

TP 53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C., Gäken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12203 · Cited by 250

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

Haferlach, C., Dicker, F., Herholz, H., Schnittger, S., Kern, W., & Haferlach, T. (2008) · Leukemia · doi:10.1038/leu.2008.143 · Cited by 247

Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.

Laï, J., Preudhomme, C., Zandecki, M., FLACTIF, M., Vanrumbeke, M., Lepelley, P., Wattel, E., & Fenaux, P. (1995) · PubMed · Cited by 197

Activation of the p53 DNA Damage Response Pathway after Inhibition of DNA Methyltransferase by 5-Aza-2′-deoxycytidine

Karpf, A. R., Moore, B. C., Ririe, T. O., & Jones, D. A. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.4.751 · Cited by 174

High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors

Manié, É., Vincent‐Salomon, A., Lehmann‐Che, J., Pierron, G., Turpin, E., Warcoin, M., Gruel, N., Lebigot, I., Sastre‐Garau, X., Lidereau, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1560 · Cited by 152

17p Deletion in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Analysis of Breakpoints and Deleted Segments by Fluorescence In Situ

Soenen, V., Preudhomme, C., Roumier, C., Daudignon, A., Laı̈, J. L., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.3.1008 · Cited by 134

Mutations in the p53 gene in myelodysplastic syndromes.

Jonveaux, P., Fenaux, P., Quiquandon, I., Jm, P., Laı̈, J. L., Mh, L.-L., Goossens, M., Bauters, F., & Berger, R. (1991) · PubMed · Cited by 121

Mutations of the P53 gene in acute myeloid leukaemia

Fenaux, P., Preudhomme, C., Quiquandon, I., Jonveaux, P., Laı̈, J. L., Vanrumbeke, M., Loucheux‐Lefebvre, M. H., Bauters, F., Berger, R., & Kerckaert, J. P. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08897.x · Cited by 117

Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy

Schnekenburger, M., Grandjenette, C., Ghelfi, J., Karius, T., Foliguet, B., Dicato, M. A., & Diederich, M. F. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.10.013 · Cited by 107

The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories

Kohlmann, A., Klein, H.-U., Weißmann, S., Bresolin, S., Chaplin, T., Cuppens, H., Haschke‐Becher, E., Garicochea, B., Grossmann, V., Hanczaruk, B., et al. (2011) · Leukemia · doi:10.1038/leu.2011.155 · Cited by 102

Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression

Oshiro, M. M., Watts, G. S., Wozniak, R. J., Junk, D. J., Muñoz-Rodríguez, J. L., Domann, F. E., & Futscher, B. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206545 · Cited by 98

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

Kelaïdi, C., Park, S., Sapena, R., Beyne‐Rauzy, O., Coiteux, V., Vey, N., Stamatoullas, A., Choufi, B., Delaunay, J., Gourin, M. P., et al. (2013) · Leukemia · doi:10.1038/leu.2013.16 · Cited by 69

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Lamarque, M., Raynaud, S., Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne‐Rauzy, O., Turlure, P., Vey, N., Récher, C., et al. (2012) · Blood · doi:10.1182/blood-2012-09-453555 · Cited by 52

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

Ghanim, V., Herrmann, H., Heller, G., Peter, B., Hadzijusufovic, E., Blatt, K., Schuch, K., Cerny‐Reiterer, S., Mirkina, I. I., Karlic, H., et al. (2012) · Blood · doi:10.1182/blood-2011-09-382770 · Cited by 38

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine

Itzykson, R., Thépot, S., Éclache, V., Quesnel, B., Dreyfus, F., Beyne‐Rauzy, O., Turlure, P., Vey, N., Récher, C., Boehrer, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.63 · Cited by 36

Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene

Nasr, A. F., Nutini, M., Palombo, B., Guerra, E., & Alberti, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206248 · Cited by 35

Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS

Traina, F., Jankowska, A. M., Visconte, V., Sugimoto, Y., Szpurka, H., Makishima, H., Jerez, A., O’Keefe, C. L., Sekeres, M. A., Advani, A. S., et al. (2011) · Blood · doi:10.1182/blood.v118.21.461.461 · Cited by 27

Inactivation of the p53 gene in leukemias and myelodysplastic syndrome (MDS) with 17p monosomy.

Preudhomme, C., Vanrumbeke, M., Laï, J., Lepelley, P., Wattel, E., & Fenaux, P. (1994) · PubMed · Cited by 10

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Bejar, R. L., Lord, A. M., Stevenson, K. E., Bar‐Natan, M., Pérez-Ladaga, A., Zaneveld, J. E., Wang, H., Caughey, B. A., Stojanov, P., Getz, G. A., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582809 · Cited by 575

Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes

Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, C., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0196-8 · Cited by 457

Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 428

Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine

Bally, C., Adès, L., Renneville, A., Preudhomme, C., Mozziconacci, J., de Thé, H., Lehmann‐Che, J., & Fenaux, P. (2012) · Blood · doi:10.1182/blood.v120.21.1706.1706 · Cited by 5

Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Müller‐Thomas, C., Rudelius, M., Rondak, I., Haferlach, T., Schanz, J., Schmidt, B., Kremer, M., Germing, U., Platzbecker, U., Peschel, C., et al. (2013) · Blood · doi:10.1182/blood.v122.21.2797.2797 · Cited by 2

P-006 Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA)

Bally, C., Adès, L., Renneville, A., Mozziconacci, J., Preudhomme, C., Dethé, H., Lehmann‐Che, J., & Fenaux, P. (2013) · Leukemia Research · doi:10.1016/s0145-2126(13)70055-9

PF553 CLONES WITH COMPLEX ABERRATIONS AND TP53 MUTATIONS RESPOND TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA

Ganster, C., Mazzeo, P., Elmaagacli, A. H., Dierks, S., Shirneshan, K., Scharnberg, P., Martin, R., Rittscher, K., Götze, K. S. S., Glaß, B., et al. (2019) · HemaSphere · doi:10.1097/01.hs9.0000560508.32787.fe

TP 53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C., Gäken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12203 · Cited by 250